Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$77.00
--
Market closed
$77.00
--
Day’s Range― - ―
52-Week Range$61.96 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)773.36K
Market Cap
$5.54B
Enterprise Value$4.18B
Total Cash (Recent Filing)$537.45M
Total Debt (Recent Filing)$144.19M
Price to Earnings (P/E)224.9
Beta1.01
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding41,442,833
10 Day Avg. Volume791,809
30 Day Avg. Volume773,359
Financial Highlights & Ratios
PEG Ratio-12.02
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue11.78
Enterprise Value/Gross Profit16.74
Enterprise Value/Ebitda102.22
Forecast
1Y Price Target
$124.17Price Target Upside61.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.98
Revenue Forecast (FY)$455.91M
Bulls Say, Bears Say
Bulls Say
Raised Guidance & GrowthManagement raised full‑year 2026 revenue guidance after Q1 strength, driven by ASP lifts and volume. A sustained, management‑backed growth target implies durable commercial traction and visibility that supports multi‑year capacity planning and investment decisions.
Unit Economics & Margin ExpansionMaterial ASP increases alongside falling or stable COGS per test drove gross margin expansion to ~73%. Improved unit economics provide a structural lever for sustainable profitability as volumes scale and underpin the company's ability to fund R&D and commercial expansion.
De‑risked Balance Sheet & CashA large cash balance and sharply reduced leverage give the company runway to fund lab expansion, clinical studies, and commercialization without near‑term financing. Strong liquidity materially lowers execution risk on multi‑year reimbursement and scale initiatives.
Bears Say
Reimbursement DependenceOncology margins and ASPs are materially linked to Medicare reimbursement progress. Delays or adverse coverage decisions would structurally suppress oncology profitability, slow adoption, and could require price concessions or higher commercial investment to sustain growth.
Revenue Recognition & AR VolatilitySignificant true‑ups and AR growth introduce persistent timing variability between billed revenue and cash receipts. That reduces visibility into sustainable cash conversion and complicates forecasting, capital allocation, and the assessment of recurring revenue quality over quarters.
Low Returns & Thin ProfitabilityAlthough profitability inflected, returns on equity and net margins remain very low. This indicates current earnings generate minimal shareholder returns and leave limited buffer against margin pressure, making long‑term value creation sensitive to cost increases or reimbursement headwinds.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $5.54B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 160 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on May 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.309.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,442,833 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.34 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.128%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$124.17 (61.26% Upside)
$124.17 (61.26% Upside)
Blogger Sentiment
Bullish
BLLN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $944.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance: very high revenue and volume growth (84% and 44% YoY), expanded ASPs and gross margins (73%), attainment of GAAP profitability and positive cash, major payer wins (Anthem, United), and notable product innovation (Unity Confirm, MRD roadmap). Primary risks noted were margin pressure as oncology scales without Medicare coverage, timing/recognition volatility from true-ups and AR, and multi-year clinical and reimbursement timelines for certain products. On balance, the positives (robust growth, profitability, payer access, new product launches, upgraded guidance, strong cash position) materially outweigh the operational and timing risks cited.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$124.17
▲(61.26% Upside)
Ownership Overview
7.78% Insiders
6.70% Mutual Funds
17.10% Other Institutional Investors
67.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---